The price of pretomanid, a key component used in the treatment of drug-resistant tuberculosis (TB), dropped by 25% in April, ...

Learn how new TB treatments show higher success rates and fewer side effects with shorter, all-oral regimens. Discover more.

Practecal, a phase 2b-3 randomised controlled trial which identified a new treatment regimen for drug resistant tuberculosis (TB), cost €33.9m (£28.95n; $38.54m), with an average cost of €61 460 per ...

A new all-oral treatment regimen for patients with drug-resistant tuberculosis has commenced in Papua New Guinea (PNG).

Following the success of recent clinical trials, several major infectious disease agencies updated treatment guidance for ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

Study Finds Three New Safe, Effective Ways to Treat Drug-Resistant Tuberculosis Jan. 29, 2025 — Study finds three new safe and effective drug regimens to fight multidrug-resistant TB.

TB Alliance's third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access ...

Pakistan's longstanding battle with tuberculosis (TB) has taken a dire turn, with the country now ranking fifth globally in the number of TB cases and fourth in drug-resistant TB. In Sindh, the ...

Global access to tuberculosis (TB) medicine pretomanid received a shot in the arm, as its price saw a 25% drop, thanks to a ...